Sign In
Buy XSNX
$0.0001
+0 (+0%)
At Close: Jun 03, 2026
Financial Contrast: NovAccess Global (OTCMKTS:XSNX) vs. Lexicon Pharmaceuticals (NASDAQ:LXRX)
02:06am, Monday, 26'th Jan 2026
NovAccess Global (OTCMKTS:XSNX - Get Free Report) and Lexicon Pharmaceuticals (NASDAQ: LXRX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contras
NovAccess Global (OTCMKTS:XSNX) versus Roivant Sciences (NASDAQ:ROIV) Financial Review
03:31am, Sunday, 18'th Jan 2026
Roivant Sciences (NASDAQ: ROIV - Get Free Report) and NovAccess Global (OTCMKTS:XSNX - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two compa
NovAccess Global Advisory on Annual Meeting of Shareholders
11:25am, Tuesday, 07'th May 2024
CLEVELAND, OH / ACCESSWIRE / May 7, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the postponement of its A
NovAccess Global Announces New License to Advance its Immunotherapy Platform
09:00am, Tuesday, 30'th Apr 2024
CLEVELAND, OH / ACCESSWIRE / April 30, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing a novel immunotherapy for patients suffering from cancers of the central nervous syste
NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders
09:00am, Friday, 01'st Mar 2024
CLEVELAND, OH / ACCESSWIRE / March 1, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today provided an update on business de
NovAccess Global Announces $10.7 Million Financing
08:00am, Tuesday, 02'nd Jan 2024
Establishes Strong Financial Base To Advance Development of Novel Cancer Immunotherapies CLEVELAND, OH / ACCESSWIRE / January 2, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company develop
NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit
04:51pm, Friday, 01'st Dec 2023
Cleveland, Ohio--(Newsfile Corp. - December 1, 2023) - NovAccess Global Inc. (OTCQB: XSNX) announced today it will be presenting at the December 7th, 2023 virtual Investor Summit. Event: December 7th
NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board
09:00am, Friday, 10'th Nov 2023
CLEVELAND, OH / ACCESSWIRE / November 10, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a preclinical biomedical company developing novel immunotherapies for brain tumor patients, today announced the app
NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform
08:30am, Thursday, 27'th Jul 2023
Development Begins on Fourth Generation of Primary Drug TLR-AD1 Targeting CNS Tumors Potential for Improved Outcomes for Cancer Patients in the $100 Billion a Year Immune Oncology Market CLEVELAND, OH
NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day
08:30am, Thursday, 13'th Jul 2023
CLEVELAND, OH / ACCESSWIRE / July 13, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its Chief Executiv
NovAccess Global to Present at World Orphan Drug Congress
09:00am, Thursday, 16'th Feb 2023
CLEVELAND, OH / ACCESSWIRE / February 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its CEO Dr. Dw
NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress
09:00am, Friday, 03'rd Feb 2023
Dr. Christopher Wheeler, NovAccess Lead Scientist, to Receive Leadership Award for his Contributions CLEVELAND, OH / ACCESSWIRE / February 3, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical co
